Abstract
Candidate gene and genome-wide association studies (GWAS) have identified 11 independent susceptibility loci associated with bladder cancer risk. To discover additional risk variants, we conducted a new GWAS of 2422 bladder cancer cases and 5751 controls, followed by a meta-analysis with two independently published bladder cancer GWAS, resulting in a combined analysis of 6911 cases and 11 814 controls of European descent. TaqMan genotyping of 13 promising single nucleotide polymorphisms with P < 1 × 10-5 was pursued in a follow-up set of 801 cases and 1307 controls. Two new loci achieved genome-wide statistical significance: rs10936599 on 3q26.2 (P = 4.53 × 10-9) and rs907611 on 11p15.5 (P = 4.11 × 10-8). Two notable loci were also identified that approached genome-wide statistical significance: rs6104690 on 20p12.2 (P = 7.13 × 10-7) and rs4510656 on 6p22.3 (P = 6.98 × 10-7); these require further studies for confirmation. In conclusion, our study has identified new susceptibility alleles for bladder cancer risk that require fine-mapping and laboratory investigation, which could further understanding into the biological underpinnings of bladder carcinogenesis.
Original language | English |
---|---|
Article number | ddt519 |
Journal | Human molecular genetics |
Volume | 23 |
Issue number | 5 |
DOIs | |
State | Published - Mar 2014 |
Fingerprint
Dive into the research topics of 'Genome-wide association study identifies multiple loci associated with bladder cancer risk'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Human molecular genetics, Vol. 23, No. 5, ddt519, 03.2014.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Genome-wide association study identifies multiple loci associated with bladder cancer risk
AU - Figueroa, Jonine D.
AU - Ye, Yuanqing
AU - Siddiq, Afshan
AU - Garcia-closas, Montserrat
AU - Chatterjee, Nilanjan
AU - Prokunina-olsson, Ludmila
AU - Cortessis, Victoria K.
AU - Kooperberg, Charles
AU - Cussenot, Olivier
AU - Benhamou, Simone
AU - Prescott, Jennifer
AU - Porru, Stefano
AU - Dinney, Colin P.
AU - Malats, Núria
AU - Baris, Dalsu
AU - Purdue, Mark
AU - Jacobs, Eric J.
AU - Albanes, Demetrius
AU - Wang, Zhaoming
AU - Deng, Xiang
AU - Chung, Charles C.
AU - Tang, Wei
AU - Bas bueno-de-mesquita, H.
AU - Trichopoulos, Dimitrios
AU - Ljungberg, Börje
AU - Clavel-chapelon, Françoise
AU - Weiderpass, Elisabete
AU - Krogh, Vittorio
AU - Dorronsoro, Miren
AU - Travis, Ruth
AU - Tjønneland, Anne
AU - Brenan, Paul
AU - Chang-claude, Jenny
AU - Riboli, Elio
AU - Conti, David
AU - Gago-dominguez, Manuela
AU - Stern, Mariana C.
AU - Pike, Malcolm C.
AU - Van den berg, David
AU - Yuan, Jian Min
AU - Hohensee, Chancellor
AU - Rodabough, Rebecca
AU - Cancel-tassin, Geraldine
AU - Roupret, Morgan
AU - Comperat, Eva
AU - Chen, Constance
AU - De vivo, Immaculata
AU - Giovannucci, Edward
AU - Hunter, David J.
AU - Kraft, Peter
AU - Lindstrom, Sara
AU - Carta, Angela
AU - Pavanello, Sofia
AU - Arici, Cecilia
AU - Mastrangelo, Giuseppe
AU - Kamat, Ashish M.
AU - Lerner, Seth P.
AU - Barton grossman, H.
AU - Lin, Jie
AU - Gu, Jian
AU - Pu, Xia
AU - Hutchinson, Amy
AU - Burdette, Laurie
AU - Wheeler, William
AU - Kogevinas, Manolis
AU - Tardón, Adonina
AU - Serra, Consol
AU - Carrato, Alfredo
AU - García-closas, Reina
AU - Lloreta, Josep
AU - Schwenn, Molly
AU - Karagas, Margaret R.
AU - Johnson, Alison
AU - Schned, Alan
AU - Armenti, Karla R.
AU - Hosain, G. M.
AU - Andriole, Gerald
AU - Grubb, Robert
AU - Black, Amanda
AU - Ryan Diver, W.
AU - Gapstur, Susan M.
AU - Weinstein, Stephanie J.
AU - Virtamo, Jarmo
AU - Haiman, Chris A.
AU - Landi, Maria T.
AU - Caporaso, Neil
AU - Fraumeni, Joseph F.
AU - Vineis, Paolo
AU - Wu, Xifeng
AU - Silverman, Debra T.
AU - Chanock, Stephen
AU - Rothman, Nathaniel
N1 - Funding Information: Funding support for individual studies that participated in the effort is as follows: ATBC (D.A.)—This research was supported in part by the Intramural Research Program of the NIH and the National Cancer Institute. Additionally, this research was supported by US Public Health Service contracts (N01-CN-45165, N01-RC-45035, N01-RC-37004 and HHSN261201000006C) from the National Cancer Institute, Department of Health and Human Services. EPIC (P.V.)—ICL—Europe Against Cancer Program of the European Commission (SANCO); IARC— International Agency for Research on Cancer; France—Ligue contre le Cancer Societe 3M, Mutuelle Generale de l’Education Nationale; Institut National de la Santé et de la Recherche Méd-icale (INSERM); Italy—Italian Association for Research on Cancer National Research Council; Spain—Health Research Fund (FIS) of the Spanish Ministry of Health; the CIBER en Epidemiología y Salud Pública (CIBERESP), Spain; ISCIII RETIC (RD06/0020); Spanish Regional Governments of Andalusia, Asturias, Basque Country, Murcia (N 6236) and Navarra and the Catalan Institute of Oncology; UK—Cancer Research UK Medical Research Council with additional support from the Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, the Wellcome Trust; The Netherlands—Dutch Ministry of Public Health Dutch Prevention Funds LK Research Funds Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF); Greece— Hellenic Ministry of Health, the Stavros Niarchos Foundation and the Hellenic Health Foundation; Germany—German Cancer Aid, German Cancer Research Center Federal Ministry of Education and Research (Grant 01-EA-9401); Sweden— Swedish Cancer Society, Swedish Scientific Council, Regional Government of Skane, Sweden and Denmark—Danish Cancer Society. FBCS (S.B.)—Ligue Contre le Cancer du Val-de-Marne; Fondation de France; Groupement d’Entreprises Franc¸aises dans la Lutte contre le Cancer; Association pour la Recherche sur le Cancer, France (TXBCS—U01 CA 127615 (X.W.), R01 CA 74880 (X.W.) and P50 CA 91846 (X.W. and C.P.D.), UT MD Anderson Cancer Centre Research Trust (X.W.), Centre for Translational and Public Health Genomics at MD Anderson Cancer Centre. LABCS (M.P.)—NIH (grants R01CA65726, R01CA114665, 1R01CA114665 and 1P01CA86871). NEBCS (D.T.S.)—Intramural research program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics and intramural contract number NCI N02-CP-01037. NHS and HPFS (I.D.V.)—CA055075, P01 CA87969, R01 CA49449, UM1 CA176726, R01 CA67262 and UM1 CA167552. PLCO (M.P.P.)—The NIH Genes, Environment and Health Initiative (GEI) partly funded DNA extraction and statistical analyses (HG-06-033-NCI-01 and RO1HL091172-01), genotyping at the Johns Hopkins University Center for Inherited Disease Research (U01HG004438 and NIH HHSN268200782096C), and study coordination at the GENEVA (N.C.) Coordination Center (U01HG004446) for the genotyping of the lung studies with controls from EAGLE study and part of the PLCO. Genotyping for the remaining part of PLCO and all ATBC and CPS-II samples were supported by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health. SBCS (D.T.S.)—Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics and intramural contract number NCI N02-CP-11015. FIS/Spain 98/1274, FIS/Spain 00/0745, PI061614 and G03/174, Fundació Marató TV3, Red Temática Investigación Cooperativa en Cáncer (RTICC), Consolíder ONCOBIO, EU-FP7-201663; and RO1-CA089715 and CA34627. WHI (C.K.)—The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201100046C, HHSN26820 1100001C, HHSN268201100002C, HHSN268201100003C, HH SN268201100004C and HHSN271201100004C.
PY - 2014/3
Y1 - 2014/3
N2 - Candidate gene and genome-wide association studies (GWAS) have identified 11 independent susceptibility loci associated with bladder cancer risk. To discover additional risk variants, we conducted a new GWAS of 2422 bladder cancer cases and 5751 controls, followed by a meta-analysis with two independently published bladder cancer GWAS, resulting in a combined analysis of 6911 cases and 11 814 controls of European descent. TaqMan genotyping of 13 promising single nucleotide polymorphisms with P < 1 × 10-5 was pursued in a follow-up set of 801 cases and 1307 controls. Two new loci achieved genome-wide statistical significance: rs10936599 on 3q26.2 (P = 4.53 × 10-9) and rs907611 on 11p15.5 (P = 4.11 × 10-8). Two notable loci were also identified that approached genome-wide statistical significance: rs6104690 on 20p12.2 (P = 7.13 × 10-7) and rs4510656 on 6p22.3 (P = 6.98 × 10-7); these require further studies for confirmation. In conclusion, our study has identified new susceptibility alleles for bladder cancer risk that require fine-mapping and laboratory investigation, which could further understanding into the biological underpinnings of bladder carcinogenesis.
AB - Candidate gene and genome-wide association studies (GWAS) have identified 11 independent susceptibility loci associated with bladder cancer risk. To discover additional risk variants, we conducted a new GWAS of 2422 bladder cancer cases and 5751 controls, followed by a meta-analysis with two independently published bladder cancer GWAS, resulting in a combined analysis of 6911 cases and 11 814 controls of European descent. TaqMan genotyping of 13 promising single nucleotide polymorphisms with P < 1 × 10-5 was pursued in a follow-up set of 801 cases and 1307 controls. Two new loci achieved genome-wide statistical significance: rs10936599 on 3q26.2 (P = 4.53 × 10-9) and rs907611 on 11p15.5 (P = 4.11 × 10-8). Two notable loci were also identified that approached genome-wide statistical significance: rs6104690 on 20p12.2 (P = 7.13 × 10-7) and rs4510656 on 6p22.3 (P = 6.98 × 10-7); these require further studies for confirmation. In conclusion, our study has identified new susceptibility alleles for bladder cancer risk that require fine-mapping and laboratory investigation, which could further understanding into the biological underpinnings of bladder carcinogenesis.
UR - http://www.scopus.com/inward/record.url?scp=84894054918&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddt519
DO - 10.1093/hmg/ddt519
M3 - Article
C2 - 24163127
AN - SCOPUS:84894054918
SN - 0964-6906
VL - 23
JO - Human molecular genetics
JF - Human molecular genetics
IS - 5
M1 - ddt519
ER -